CCR2 and renal fibrosis: In several preclinical studies, MCP-1 and CCR2 antagonists, such as mNOX-E36-3’PEG, RS102895, and RS504393, have been successfully used to block the MCP-1/CCR2 axis conduction in treating renal fibrosis.